key: cord-0815754-n6pov9c6 authors: Bravi, F.; Flacco, M. E.; Carradori, T.; Volta, C. A.; Cosenza, G.; De Togni, A.; Acuti Martellucci, C.; Parruti, G.; Mantovani, L.; Manzoli, L. title: Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens date: 2020-05-23 journal: nan DOI: 10.1101/2020.05.21.20109082 sha: 535d9c85ea534bff5c8853d45963569e09ac548b doc_id: 815754 cord_uid: n6pov9c6 Aims: This retrospective case-control study was aimed at identifying potential independent predictors of severe/lethal COVID-19, including the treatment with Angiotensin-Converting Enzyme inhibitors (ACEi) and/or Angiotensin II Receptor Blockers (ARBs). Methods and Results: All adults with SARS-CoV-2 infection in two Italian provinces were followed for a median of 24 days. ARBs and/or ACEi treatments, and hypertension, diabetes, cancer, COPD, renal and major cardiovascular diseases (CVD) were extracted from clinical charts and electronic health records, up to two years before infection. The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (154 deaths; mean age 79.3 years; 70.8% hypertensive, 42.2% with CVD). The youngest deceased person aged 44 years. Among hypertensive subjects (n=543), the proportion of those treated with ARBs or ACEi were 88.4%, 78.7% and 80.6% among patients with mild, severe and very severe/lethal disease, respectively. At multivariate analysis, no association was observed between therapy and disease severity (Adjusted OR for very severe/lethal COVID-19: 0.87; 95% CI: 0.50-1.49). Significant predictors of severe disease were older age (with AORs largely increasing after 70 years of age), male gender (AOR: 1.76; 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18), CVD (AOR: 1.88; 1.32-2.70) and COPD (1.88; 1.11-3.20). Only gender, age and diabetes also predicted very severe/lethal disease. Conclusion: No association was found between COVID-19 severity and treatment with ARBs and/or ACEi, supporting the recommendation to continue medication for all patients unless otherwise advised by their physicians. Novel coronavirus disease (COVID-19) is spreading worldwide, and has caused over 250,000 deaths so far 49 [1] . The mortality rate varies widely by age and across individuals, ranging from 0.2% among healthy, 50 young-adults, to >10% among older persons with pre-existing conditions [1] . Although the pharmacological treatment was not assessed, the first observational studies on patients with 52 severe disease reported a high prevalence of comorbidities that are often treated with angiotensin converting 53 enzyme (ACE) inhibitors, such as cerebrovascular diseases, coronary heart disease, hypertension and 54 diabetes [2] [3] [4] . Observing that human pathogenic coronaviruses bind their target cells through angiotensin-55 converting enzyme 2 (ACE2) [5] , and that the expression of ACE2 is substantially increased in diabetics and 56 patients who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) [5, 6], Fang 57 and colleagues hypothesized that the increased expression of ACE2 would facilitate infection with Severe 58 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), thus the hypertension treatment with ACE2-59 stimulating drugs, as well as ACE2 polymorphisms, might increase the risk of developing severe COVID-19 60 [7] . Consequently, this would lead to a serious conflict regarding treatment, because ACE2 reduces 61 inflammation and has been suggested as a potential new therapy for inflammatory lung diseases, cancer, 62 diabetes, and hypertension [7] [8] [9] [10] [11] . In the wake of two preliminary cohort studies reporting a lower [12] (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. First, the differences across groups with mild, severe or very severe/lethal disease were evaluated using t-test 100 (for continuous variables) and Mantel-Haenzsel chi-squared test for categorical ones. A sample restricted to 101 hypertensive subjects was used to compare the subjects treated and untreated with ACE inhibitors or ARBs. 102 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20109082 doi: medRxiv preprint 5 Multivariate logistic regression was used to investigate the potential independent predictors of severe or very 103 severe/lethal COVID-19. Four models were built, two were restricted to hypertensive subjects (A and B), 104 and two included the total sample (Models C and D) and. Models A and C were fit to predict severe or very 105 severe disease (grouped together), while Models B and D to predict very severe/lethal disease only (and 106 repeated to predict death, with similar results, which have not been shown to avoid redundancy). All 107 recorded variables were included a priori in all models, with the exception of treatments with ACE inhibitors 108 and ARBs, that were excluded from Models C and D because of multicollinearity with hypertension. Standard diagnostic procedures were adopted to check all models validity: influential observation analysis The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 117 192 (12.0%) very severe or lethal disease (Table 1) . 154 subjects deceased (mean age 79.3 years; 54.6% 118 males); of them, 70.8% were hypertensive, 42.2% were diagnosed a CVD; 27.9% diabetics. Twenty subjects 119 with very severe disease were younger than 60 years; the youngest being a male aged 33 years. Of those 120 deceased, eight were younger than 60 years, and the youngest was a female aged 44 years. At univariate analysis, as compared to the subjects with mild disease, those with severe or very severe/lethal 122 disease were significantly more likely to be older, diabetics, hypertensive, diagnosed with COPD, CVD, and 123 renal disease, and treated with ARBs and/or ACE inhibitors (all p<0.05). Among hypertensive subjects 124 (n=543), however, the proportion of those treated with ARBs or ACE inhibitors were higher among those 125 with asymptomatic/mild disease (88.4%, versus 78.7% and 80.6% among patients with severe and very 126 severe/lethal disease, respectively -Table 1; Figure 1 ). 127 128 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 152 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20109082 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . With regard to the role of the other risk factors that have been suggested for severe COVID-19, including 195 age, male gender, hypertension, diabetes, COPD, and major cardiovascular diseases, it has been correctly 196 argued that, so far, available data were unadjusted, thus the relative importance of underlying health 197 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . conditions was unclear [9, 17] . In this study, we found support for a potential role of gender, diabetes, COPD 198 and CVD, beyond age, in COVID-19 progression to a severe disease, whereas only gender and diabetes 199 significantly increased the risk of a lethal or very severe outcome. Thus, the present study confirms prior In addition to a relatively small sample, another limitation of the present study is the lack of tobacco smoking 209 and body mass index among the variables that have been recorded, because we could not extract such 210 information for half of the deceased subjects, as well as for many of those that were not hospitalized. In conclusions, the present study did not find any association between COVID-19 severity and treatment 212 with ARBs, ACE inhibitors, or both, and confirms previous findings in supporting the recommendation of 213 several scientific societies to continue ARBs or ACE inhibitors medication for all patients, unless otherwise 214 advised by their physicians, who should thus be reassured. The adjusted analyses substantially confirm prior 215 reports, indicating that the risk of severe or lethal COVID-19 largely and significantly increases among the 216 elderly, males, diabetics, and those with COPD or major cardiovascular diseases. 217 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. Access to data: The complete dataset used in this work is available in Appendix S1. 229 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20109082 doi: medRxiv preprint COVID-19 Coronavirus Outbreak Clinical course and outcomes of critically ill patients 233 with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective Clinical Characteristics of Coronavirus 237 Disease 2019 in China. The New England journal of medicine Clinical characteristics of 140 240 patients infected with SARS-CoV-2 in Wuhan Receptor recognition by novel coronavirus from 243 Wuhan: An analysis based on decade-long structural studies of SARS The vasoprotective axes of the renin-angiotensin system: Physiological 247 relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases Are patients with hypertension and diabetes mellitus at increased 251 risk for COVID-19 infection? Coronavirus Disease 2019 (COVID-19) Infection and Renin 254 COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin 257 Receptor Blockers: What Is the Evidence? Drugs and the renin-angiotensin system in covid-19 Association of Inpatient Use of Angiotensin 266 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With 267 Hypertension Hospitalized With COVID-19 Association of Renin-Angiotensin System Inhibitors With 270 Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 271 (COVID-19) Infection in Wuhan Cardiovascular Disease, Drug Therapy, and 274 Mortality in Covid-19 Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Covid-19: risk factors for severe disease and death Case-Fatality Rate and Characteristics of Patients Dying in 285 Relation to COVID-19 in Italy System Inhibitors in Patients with Covid-19 Renin-Angiotensin System Blockers and the COVID-19 At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers COVID-19 and the cardiovascular system No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted System and Covid-19 Switching antihypertensive therapy in times of COVID-19: why we should 305 wait for the evidence SARS-CoV2: should 308 inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? European heart journal All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 23, 2020.